Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 5/20 | 0.50 |
| ▸ | WNT3A | P56704 | 5/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.45 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17341982 | 0.89 | CTNNB1 (0.50) | CTNNB1WNT3AGPR84GABRA1GABRB2 | |
| SCHEMBL17341974 | 0.85 | GABRA1 (0.47) | CTNNB1WNT3AGPR84GABRA1GABRB2 | |
| SCHEMBL17341967 | 0.82 | GABRA1 (0.47) | CTNNB1WNT3AGABRA1GABRB2ADAM17 | |
| SCHEMBL7842860 | 0.80 | LMNA (0.54) | CTNNB1WNT3AGPR84ADAM17NPC1 | |
| SCHEMBL10344616 | 0.79 | GPR84 (0.58) | CTNNB1WNT3AGPR84GAAKDM4E | |
| SCHEMBL15356576 | 0.79 | PBRM1 (0.56) | CTNNB1WNT3AGPR84NPC1BRPF1 | |
| SCHEMBL16791407 | 0.78 | GPR84 (0.49) | CTNNB1WNT3AGPR84ADAM17NPC1 | |
| SCHEMBL17341972 | 0.77 | CTNNB1 (0.40) | CTNNB1WNT3ALMNAKDM4EMEN1 | |
| SCHEMBL3995494 | 0.76 | GPR84 (0.51) | CTNNB1WNT3AGPR84NPC1BRPF1 | |
| SCHEMBL19821107 | 0.75 | CTNNB1 (0.41) | CTNNB1WNT3ALMNAKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180029990-A1 | COMPOSITION AND METHOD FOR PREVENTION, MITIGATION OR TREATMENT OF AN ENTEROPATHOGENIC BACTERIAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-01 | — | — | US | disclosed |
| US-9790186-B2 | Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2017-10-17 | — | — | US | disclosed |
| US-20150361045-A1 | COMPOSITION AND METHOD FOR PREVENTION, MITIGATION OR TREATMENT OF AN ENTEROPATHOGENIC BACTERIAL INFECTION | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361045-A1 | COMPOSITION AND METHOD FOR PREVENTION, MITIGATION OR TREATMENT OF AN ENTEROPATHOGENIC BACTERIAL INFECTION | FABP2, LRBA, VIP | CTNNB1 2003/4885WNT3A 1157/4885GPR84 3795/4885 |
| US-20180029990-A1 | COMPOSITION AND METHOD FOR PREVENTION, MITIGATION OR TREATMENT OF AN ENTEROPATHOGENIC BACTERIAL INFECTION | FABP2, LRBA, VIP | CTNNB1 2003/4885WNT3A 1157/4885GPR84 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.